AR117735A1 - ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO - Google Patents
ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USOInfo
- Publication number
- AR117735A1 AR117735A1 ARP190103841A ARP190103841A AR117735A1 AR 117735 A1 AR117735 A1 AR 117735A1 AR P190103841 A ARP190103841 A AR P190103841A AR P190103841 A ARP190103841 A AR P190103841A AR 117735 A1 AR117735 A1 AR 117735A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- cell receptor
- antibody
- trbv
- region
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a un anticuerpo humanizada monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a la familia TRBV9 del receptor de células T humanas. La presente también se refiere a un ácido nucleico que codifica dicho anticuerpo o fragmento de unión al antígeno del mismo, un vector de expresión, un método para preparar dicho anticuerpo, y el uso de dicho anticuerpo en el tratamiento de las enfermedades o trastornos asociados con la familia de receptores de células T humanas. La presente se dirige a la generación de anticuerpos que se pueden usar para tratar, en particular AS, enfermedad celíaca y enfermedades sanguíneas malignas, cuya patogénesis involucra los TCR de la familia TRBV9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018146029A RU2711871C1 (ru) | 2018-12-25 | 2018-12-25 | Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения |
Publications (1)
Publication Number | Publication Date |
---|---|
AR117735A1 true AR117735A1 (es) | 2021-08-25 |
Family
ID=69184146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103841A AR117735A1 (es) | 2018-12-25 | 2019-12-23 | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |
Country Status (25)
Country | Link |
---|---|
US (1) | US20220056133A1 (es) |
EP (1) | EP3904387A4 (es) |
JP (1) | JP7507160B2 (es) |
KR (1) | KR20210118843A (es) |
CN (1) | CN113692412A (es) |
AR (1) | AR117735A1 (es) |
AU (1) | AU2019416787A1 (es) |
BR (1) | BR112021012550A2 (es) |
CA (1) | CA3124800A1 (es) |
CL (1) | CL2021001704A1 (es) |
CO (1) | CO2021008204A2 (es) |
CR (1) | CR20210353A (es) |
EA (1) | EA202100199A1 (es) |
EC (1) | ECSP21046332A (es) |
IL (1) | IL284367A (es) |
JO (1) | JOP20210168A1 (es) |
MA (1) | MA53688B1 (es) |
MX (1) | MX2021007718A (es) |
PE (1) | PE20211792A1 (es) |
PH (1) | PH12021551535A1 (es) |
RU (1) | RU2711871C1 (es) |
SG (1) | SG11202106974SA (es) |
TW (1) | TW202033557A (es) |
WO (1) | WO2020139171A1 (es) |
ZA (1) | ZA202104356B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
CN116510006A (zh) * | 2022-01-31 | 2023-08-01 | 拜奥卡德联合股份公司 | 抗trbv9抗体的药物组合物及其用途 |
WO2024039268A1 (ru) * | 2022-08-18 | 2024-02-22 | Акционерное общество "БИОКАД" | Способ лечения заболевания, опосредованного т-лимфоцитами |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223426A (en) | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
MXPA05000511A (es) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
KR20120044941A (ko) * | 2009-06-25 | 2012-05-08 | 프레드 헛친슨 켄서 리서치 센터 | 적응 면역의 측정방법 |
TW201208701A (en) | 2010-07-12 | 2012-03-01 | Daiichi Sankyo Co Ltd | Anti-EPHA2 antibodies and uses thereof |
US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
LT2991683T (lt) | 2013-05-02 | 2019-12-27 | Glykos Finland Oy | Glikoproteino arba glikano konjugatai su toksine medžiaga |
EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
US11732020B2 (en) | 2016-06-17 | 2023-08-22 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
EP3538113A4 (en) * | 2016-11-14 | 2020-08-19 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN SPECIFIC TCRs AND THEIR USES |
JP7162607B2 (ja) * | 2017-02-27 | 2022-10-28 | 中外製薬株式会社 | 抗hla-dq2.5/8抗体およびセリアック病の治療のためのその使用 |
CN107502671B (zh) * | 2017-10-12 | 2020-05-05 | 中国医学科学院肿瘤医院 | 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用 |
RU2694412C9 (ru) * | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
-
2018
- 2018-12-25 RU RU2018146029A patent/RU2711871C1/ru active
-
2019
- 2019-12-23 AR ARP190103841A patent/AR117735A1/es unknown
- 2019-12-24 JP JP2021537704A patent/JP7507160B2/ja active Active
- 2019-12-24 CR CR20210353A patent/CR20210353A/es unknown
- 2019-12-24 CA CA3124800A patent/CA3124800A1/en active Pending
- 2019-12-24 PE PE2021001079A patent/PE20211792A1/es unknown
- 2019-12-24 KR KR1020217023567A patent/KR20210118843A/ko unknown
- 2019-12-24 EA EA202100199A patent/EA202100199A1/ru unknown
- 2019-12-24 WO PCT/RU2019/050257 patent/WO2020139171A1/ru unknown
- 2019-12-24 SG SG11202106974SA patent/SG11202106974SA/en unknown
- 2019-12-24 MX MX2021007718A patent/MX2021007718A/es unknown
- 2019-12-24 JO JOP/2021/0168A patent/JOP20210168A1/ar unknown
- 2019-12-24 MA MA53688A patent/MA53688B1/fr unknown
- 2019-12-24 CN CN201980092914.6A patent/CN113692412A/zh active Pending
- 2019-12-24 EP EP19904442.1A patent/EP3904387A4/en active Pending
- 2019-12-24 US US17/417,570 patent/US20220056133A1/en active Pending
- 2019-12-24 AU AU2019416787A patent/AU2019416787A1/en active Pending
- 2019-12-24 TW TW108147433A patent/TW202033557A/zh unknown
- 2019-12-24 BR BR112021012550-7A patent/BR112021012550A2/pt unknown
-
2021
- 2021-06-23 CO CONC2021/0008204A patent/CO2021008204A2/es unknown
- 2021-06-24 ZA ZA2021/04356A patent/ZA202104356B/en unknown
- 2021-06-24 IL IL284367A patent/IL284367A/en unknown
- 2021-06-24 CL CL2021001704A patent/CL2021001704A1/es unknown
- 2021-06-24 EC ECSENADI202146332A patent/ECSP21046332A/es unknown
- 2021-06-25 PH PH12021551535A patent/PH12021551535A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220056133A1 (en) | 2022-02-24 |
AU2019416787A1 (en) | 2021-08-12 |
CR20210353A (es) | 2021-12-20 |
CL2021001704A1 (es) | 2022-01-28 |
MA53688B1 (fr) | 2023-03-31 |
MX2021007718A (es) | 2021-08-05 |
EA202100199A1 (ru) | 2021-12-02 |
JP7507160B2 (ja) | 2024-06-27 |
RU2711871C1 (ru) | 2020-01-23 |
TW202033557A (zh) | 2020-09-16 |
IL284367A (en) | 2021-08-31 |
CA3124800A1 (en) | 2020-07-02 |
CO2021008204A2 (es) | 2021-08-30 |
SG11202106974SA (en) | 2021-07-29 |
ECSP21046332A (es) | 2021-07-30 |
EP3904387A4 (en) | 2022-09-07 |
ZA202104356B (en) | 2022-09-28 |
MA53688A1 (fr) | 2022-06-30 |
BR112021012550A2 (pt) | 2021-09-14 |
PE20211792A1 (es) | 2021-09-09 |
EP3904387A1 (en) | 2021-11-03 |
JP2022515820A (ja) | 2022-02-22 |
CN113692412A (zh) | 2021-11-23 |
JOP20210168A1 (ar) | 2023-01-30 |
KR20210118843A (ko) | 2021-10-01 |
WO2020139171A1 (ru) | 2020-07-02 |
PH12021551535A1 (en) | 2022-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000907A1 (es) | Anticuerpos de unión a gprc5d | |
ECSP21046332A (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso | |
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
ECSP19010852A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
EA202191666A1 (ru) | Антитела к il-27 и их применение | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
ECSP19018367A (es) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
EA202092497A1 (ru) | Анти-cd27 и анти-pd-l1 антитела и биспецифические конструкции | |
AR118787A1 (es) | Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades |